Tebotelimab
Modify Date: 2024-04-03 13:35:16
Tebotelimab structure
|
Common Name | Tebotelimab | ||
|---|---|---|---|---|
| CAS Number | 2245725-04-4 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TebotelimabTebotelimab (MGD-013) is a human IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity[1][2][3]. |
| Name | Tebotelimab |
|---|
| Description | Tebotelimab (MGD-013) is a human IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | MGD013 (0.39, 1.56, 6.25, 25 nM; 48 小时) 增强人 PBMC 中 T 细胞抗原受体驱动的激活。与 PD-1 + LAG-3 mAb 组合相比，MGD013 显示增强的葡萄球菌肠毒素 B (SEB; 0.5mg/mL) 诱导 IFN-γ 分泌[1]。 |
| References |
| No Any Chemical & Physical Properties |